Non-inferiority of Portable Versus Desktop Spirometry
Primary Purpose
Asthma, COPD
Status
Completed
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
AioCare
Spirometer USB CPFS/D (MGC Diagnostics)
Sponsored by

About this trial
This is an interventional diagnostic trial for Asthma focused on measuring Asthma, COPD, Mobile Spirometry
Eligibility Criteria
Inclusion Criteria:
- Age>18.
- Diagnosed asthma or COPD
- Signed consent to participation in the research experiment.
- Ability to comply with the spirometry protocol.
Exclusion Criteria:
- Pregnant females (based on declaration; no pregnancy tests are planned before the test).
- Recent myocardial infarction (<30 days).
- Known thoracic, aortic or cerebral aneurysm.
- Recent stroke, eye surgery, thoracic/abdominal surgery.
- Haemoptysis.
- Recent pneumothorax.
- Uncontrolled hypertension.
- Pulmonary Embolism.
- Angina.
- Chest or abdominal pain of any etiology.
- Oral or facial pain exacerbated by a mouthpiece.
- Stress incontinence.
- Dementia or state of confusion. 14, Acute Diarrhea
Sites / Locations
- National Institute for Tuberculosis and Lung Diseases
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Sequence A
Sequence B
Arm Description
Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
Outcomes
Primary Outcome Measures
Non-inferiority of PEF between AioCare and CPFS/D USB Spirometer
Comparison of Peak Expiratory Flow obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Non-inferiority of FEV1 between AioCare and CPFS/D USB Spirometer
Comparison of Forced Expiratory Volume in the first second (FEV1) obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Non-inferiority of FVC between AioCare and CPFS/D USB Spirometer
Comparison of Forced Vital Capacity (FVC) obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Secondary Outcome Measures
Full Information
NCT ID
NCT03894475
First Posted
March 19, 2019
Last Updated
March 26, 2019
Sponsor
National Institute for Tuberculosis and Lung Diseases, Poland
Collaborators
Healthup Sp. z o.o.
1. Study Identification
Unique Protocol Identification Number
NCT03894475
Brief Title
Non-inferiority of Portable Versus Desktop Spirometry
Official Title
Non-inferiority of Portable Versus Desktop Spirometry
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
December 18, 2017 (Actual)
Primary Completion Date
June 21, 2018 (Actual)
Study Completion Date
June 21, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute for Tuberculosis and Lung Diseases, Poland
Collaborators
Healthup Sp. z o.o.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators compared the ventilation parameters for volume and flow obtained from standard spirometry procedures from patients presently monitored and treated for asthma or chronic obstructive pulmonary disease (COPD) using AioCare (HealthUp Sp. z o.o., Serial Number: MS082017005412, software version: MySpiroo app 1.1.14) as the tested device and Spirometer USB CPFS/D (MGC Diagnostics) as the reference, which required calibration prior to each session. Spirometry measurements were performed on sixty-two patients (forty-four females (58±17 years old) and eighteen males (52±19 years old)) at the Institute of Tuberculosis and Lung Disease in Warsaw, Poland. Participants were asked to perform correct spirometry examinations (which means at least three technically correct exhales and meeting repeatability criteria for FEV1 and FVC) on both measuring devices with a five-minute break between devices to prevent respiratory muscle fatigue. The highest value from all acceptable spirometry results was then used for analysis. All spirometry examinations followed ERS/ATS standards.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, COPD
Keywords
Asthma, COPD, Mobile Spirometry
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence A
Arm Type
Active Comparator
Arm Description
Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
Arm Title
Sequence B
Arm Type
Active Comparator
Arm Description
Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
Intervention Type
Device
Intervention Name(s)
AioCare
Intervention Description
AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
Intervention Type
Device
Intervention Name(s)
Spirometer USB CPFS/D (MGC Diagnostics)
Intervention Description
Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
Primary Outcome Measure Information:
Title
Non-inferiority of PEF between AioCare and CPFS/D USB Spirometer
Description
Comparison of Peak Expiratory Flow obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Time Frame
6 months
Title
Non-inferiority of FEV1 between AioCare and CPFS/D USB Spirometer
Description
Comparison of Forced Expiratory Volume in the first second (FEV1) obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Time Frame
6 months
Title
Non-inferiority of FVC between AioCare and CPFS/D USB Spirometer
Description
Comparison of Forced Vital Capacity (FVC) obtained during a standard dynamic spirometry measured with AioCare (HealthUp) and reference spirometer (MGC)
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age>18.
Diagnosed asthma or COPD
Signed consent to participation in the research experiment.
Ability to comply with the spirometry protocol.
Exclusion Criteria:
Pregnant females (based on declaration; no pregnancy tests are planned before the test).
Recent myocardial infarction (<30 days).
Known thoracic, aortic or cerebral aneurysm.
Recent stroke, eye surgery, thoracic/abdominal surgery.
Haemoptysis.
Recent pneumothorax.
Uncontrolled hypertension.
Pulmonary Embolism.
Angina.
Chest or abdominal pain of any etiology.
Oral or facial pain exacerbated by a mouthpiece.
Stress incontinence.
Dementia or state of confusion. 14, Acute Diarrhea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piotr Boros, Prof. dr hab. n. med.
Organizational Affiliation
National Institute for Tuberculosis and Lung Diseases, Poland
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute for Tuberculosis and Lung Diseases
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
01-138
Country
Poland
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Non-inferiority of Portable Versus Desktop Spirometry
We'll reach out to this number within 24 hrs